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ohe  production  of  recombinant  proteins  began  in  1980,  and
seful  compounds,  such  as  human  insulins,  were  generated.
his  biotechnological  strategy  facilitated  the  treatment  of
iabetes  mellitus  while  at  the  same  time  decreasing  intoler-
nce  reactions  caused  by  the  use  of  animal-derived  insulins.
The  use  of  recombinant  proteins  continued  growing,  and,
urrently,  erythropoietin  and  growth  factors  are  available,
mong  others.
Furthermore,  the  discovery  that  previously  sensitized
nimal  serum  for  the  treatment  of  diphtheria  was  possible
nd  effective,  suggested  that  the  antibodies  it  contained
ere  a  therapeutic  strategy.
The  previous  observation  was  followed  by  the  develop-
ent  of  the  hybridoma  technique,  which  Kohler  and  Milsten,
inners  of  the  1984  Nobel  Prize,  had  been  working  on  since
he  70s.  Their  work  led  to  the  generation  of  monoclonal  anti-
odies,  which,  in  addition  to  their  multiple  applications  in
xperimental  and  diagnostic  processes,  are  used  as  treat-
ent  strategies.
A  murine  antibody  directed  against  the  human  CD3
olecule,  expressed  by  the  T  lymphocytes,  was  used  for
he  ﬁrst  time  in  1983,  inducing  a  depletion  of  these  cells.DOI of original article:
ttp://dx.doi.org/10.1016/j.rccar.2016.09.002
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pen access article under the CC BY-NC-ND license (http://creativecommhis  antibody,  the  ﬁrst  one  used  in  humans  for  therapeutic
urposes  in  the  management  of  kidney  transplant  rejection,
as  considered  to  be  an  effective  strategy  for  many  years.
n  1991,  the  successful  use  of  this  antibody  for  the  ﬁrst
ime  in  our  country,  for  the  treatment  of  a  patient  with  kid-
ey  rejection,  was  published  in  the  Revista  Colombiana  de
irugía  [Colombian  Journal  of  Surgery].
After  using  murine-derived  antibodies  for  the  manage-
ent  of  acute  conditions,  and  having  demonstrated  their
ffectiveness  and  safety,  the  possibility  arose  of  imple-
enting  this  type  of  strategies  for  chronic  conditions.
he  observation  of  so-called  ¨serum  sicknes¨s  in  which  the
mmune  system  recognizes  the  foreign  proteins  contained  in
he  applied  serum  and  which  induce  an  immune  response,
enerate  concern  regarding  the  long-term  use  of  these
ntibodies.  This  immune  response  leads  to  serum  inactiva-
ion  or  to  the  formation  of  immune  complexes  which  may
recipitate  in  the  organs  and  induce  cellular  and  comple-
ent  activation  and  subsequent  tissue  lesions.  Due  to  this,
iotechnological  strategies  were  developed  which  would
educe  the  amount  of  foreign  protein.  The  strategy  was  the
se  of  genetic  engineering  and  the  generation  of  antibodies
hich  would  reduce  the  content  of  murine  proteins.  These
ntibodies  were  formed  by  variable  murine-derived  regions
btained  from  mice  sensitized  with  the  antigen  of  inter-
st,  and  constant  fractions  of  the  antibody  which  came  from
uman  genes.  In  light  of  this  composition,  these  antibodies
ere  called  chimeric.
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Based  on  this  technology,  treatments  were  developed
which  are  in  use  today,  such  as  rituximab,  directed  against  a
B  lymphocyte  protein  (CD20),  and  which  induces  a  depletion
of  these  lymphocytes,  indicated  in  the  treatment  of  lym-
phomas  and  rheumatoid  arthritis;  or  baxiliximab,  directed
against  the  CD25  molecule  of  the  T  lymphocytes,  and  indi-
cated  in  kidney  transplant  rejection.
The  persistence  of  a  murine  component  for  use  in  chronic
diseases  was  still  a  challenge  due  to  the  possibility  that  these
proteins  might  continue  to  be  immunogenic.  The  techno-
logical  advances  continued,  in  order  to  reduce  the  murine
component  to  its  minimal  expression,  and  humanized  anti-
bodies  were  obtained  such  as  tocilizumab,  indicated  in
rheumatoid  arthritis,  or  daclizumab,  useful  in  the  treatment
of  multiple  sclerosis.
New  technologies,  such  as  ¨phage  libraries¨,  which
allow  the  generation  of  proteins  with  human-derived
sequences  which  are  speciﬁc  for  the  recognition  of  cer-
tain  antigens,  are  currently  used  for  generating  completely
human  monoclonal  antibodies,  with  demonstrated  effec-
tiveness  in  multiple  chronic  illnesses;  among  these  is
adalimumab  for  rheumatoid  arthritis,  or  ustekinumab  for
psoriasis.
However,  biotechnology  has  not  just  stayed  in  the  ﬁeld
of  monoclonal  antibodies,  the  generation  of  fusion  proteins,
the  frequent  use  of  recombinant  proteins,  and  the  gener-
ation  of  vaccines  with  more  selective  antigens  and  more
efﬁcient  adjuvants  which  provide  a  longer-lasting  immuno-
logical  memory;  rather,  it  has  taken  the  lead  as  part  of  our
daily  therapeutic  strategies.
In  cardiology,  biotechnology  has  also  been  used  for  many
years,  and  covers  various  aspects  of  diseases:  antidotes
such  as  digibind,  a  sheep-derived  Fab  antibody  fraction,
indicated  in  digoxin  intoxication,  and  idarucizumab,  a
humanized  antibody,  whose  Fab  fraction  combines  with
dabigatran  and  reverts  its  effect  from  the  ﬁrst  minute
of  infusion.  In  addition,  abciximab  has  been  used  to
avoid  thrombotic  complications.  Abciximab  is  a  chimeric
monoclonal  antibody  directed  against  the  IIb/IIIa  platelet
glycoprotein,  which  is  useful  in  the  prevention  of  throm-
botic  complications  in  percutaneous  coronary  interventions
for  acute  myocardial  infarctions.In  the  management  of  heart  transplants,  as  in  kidney
transplants,  murine,  chimeric  and  humanized  antibodies
have  been  used,  such  as  muromonab,  basiliximab,  and
daclizumab.
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This  type  of  medications  has  also  been  used  in  more
peciﬁc  events  such  as  the  blocking  of  membrane  attack
omplex  formation  (C5b-9)  by  the  antibody  directed  against
he  C5  complement  protein,  with  the  aim  to  diminish  the
poptosis  that  occurs  during  acute  myocardial  infarction
ith  ST  elevation,  or  in  heart  surgery,  especially  in  coronary
evascularization,  in  order  to  minimize  cellular  damage  due
o  ischemia  and  reperfusion.
More  recently,  the  management  of  hyperlipidemia
as  been  proposed,  speciﬁcally  for  management  of  LDL
levations,  with  biotechnological  medications  directed
gainst  the  proprotein  convertase  subtilisin/kexin  type  9
PCSK9),  such  as  evolocumab  (AMG  145),  alirocumab  and
ococizumab.
New  molecules  would  be  discovered  in  the  pathogenesis
f  acute  and  chronic  illnesses,  new  cells  will  be  described
ith  determinant  roles  in  some  of  them,  and  this  will  make
hem  possible  therapeutic  targets  to  be  managed  with  a
iotechnological  approach.
The  advances  have  allowed  biotechnological  products  to
e  ever  safer,  more  effective  and  economical,  and  have  led
o  a greater  number  of  diseases  and  patients  being  treated
ith  these  medications.  Thus,  the  importance  of  knowing
hem,  and  understanding  their  origin  and  their  physiology  in
rder  to  feel  more  secure  in  having  them  as  a  therapeutic
ption.
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